석고 및 부목 시장 : 제품 유형, 소재, 용도, 최종 사용자, 유통 채널별 - 세계 시장 예측(2026-2032년)

The Casting & Splinting Market is projected to grow by USD 4.80 billion at a CAGR of 8.25% by 2032.

Executive Introduction to Casting & Splinting

The casting & splinting market is anchored in the essential clinical need to stabilize fractures, sprains, tendon injuries, post-operative repairs, and trauma-related musculoskeletal conditions. Demand is supported by durable epidemiological drivers, including aging populations, sports participation, occupational injuries, road traffic injuries, and the global burden of osteoporosis; the International Osteoporosis Foundation reports more than 8.9 million osteoporotic fractures annually worldwide, while the World Health Organization cites about 1.19 million road traffic deaths each year, with many more nonfatal injuries requiring immobilization.

For healthcare providers and manufacturers, the opportunity is shifting from volume-based supply of plaster bandages and fiberglass casts toward evidence-informed immobilization solutions that improve fit, comfort, hygiene, workflow efficiency, skin safety, and recovery monitoring. Relevant growth themes include orthopedic casting, splinting products, fracture immobilization, thermoplastic splints, fiberglass casting tape, plaster of Paris bandages, 3D-printed orthoses, pediatric casting, sports injury splints, and outpatient orthopedic care.

Transformative Shifts in Orthopedic Immobilization

The landscape is being reshaped by material innovation, care migration, and patient-centered design. Traditional plaster of Paris remains relevant for conformability and cost-sensitive care, but fiberglass casts, synthetic casting tapes, low-temperature thermoplastics, waterproof liners, breathable padding, and prefabricated splints are gaining preference where lightweight performance, faster application, radiolucency, and lower maintenance are priorities.

At the care-delivery level, fracture management is moving beyond inpatient orthopedic departments into emergency departments, urgent care centers, ambulatory surgery centers, sports medicine clinics, rehabilitation settings, and home-follow-up pathways. This shift rewards suppliers that can offer standardized kits, faster training, digital sizing tools, sustainable packaging, clear patient instructions, and products compatible with reimbursement, infection-prevention, and clinical documentation requirements.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is creating cumulative value across casting & splinting by improving diagnosis, product selection, workflow automation, and follow-up monitoring. AI-enabled radiology support can help clinicians identify fractures earlier, while computer vision and measurement algorithms can support customized splint design, limb-shape assessment, pressure-risk evaluation, and 3D-print-ready orthotic workflows. The U.S. FDA has authorized hundreds of AI/ML-enabled medical devices, showing that clinical AI adoption is moving from experimentation into regulated healthcare use.

AI also strengthens manufacturing and supply-chain resilience. Demand forecasting, inventory optimization, defect detection in composite materials, automated quality checks, and patient-specific digital instructions can reduce waste and improve availability of high-usage products such as fiberglass tape, stockinette, padding, plaster rolls, and splint sheets. Leaders should treat AI as an assistive layer governed by clinical validation, cybersecurity, data privacy, human oversight, and transparent performance monitoring.

Key Regional Insights: Asia-Pacific, North America, Europe, Latin America, Middle East, and Africa

Asia-Pacific is a high-volume growth arena due to large populations, expanding trauma care, rising disposable income, and investments in hospital infrastructure across China, India, Japan, South Korea, Australia, and ASEAN markets. The region's demand is reinforced by road traffic injuries, sports participation, and increasing access to orthopedic and emergency care. North America remains a premium innovation hub, supported by high healthcare spending, developed emergency care networks, orthopedic specialization, sports medicine demand, occupational injury management, and rapid adoption of advanced bracing, waterproof casting, and digital orthotic tools.

Europe shows steady demand driven by aging demographics, fracture-prevention programs, and established reimbursement systems, with Germany, France, Italy, Spain, and the United Kingdom emphasizing quality, safety, regulatory compliance, and sustainability. Latin America is advancing through private hospital expansion and public trauma-care needs in Brazil and Mexico, where affordability and distribution reach remain critical. The Middle East benefits from healthcare modernization in GCC economies, expanding specialty care, and medical infrastructure investment, while Africa presents long-term demand tied to trauma burden, urbanization, workforce injuries, and the need for affordable, durable immobilization products suited to varied clinical settings.

Key Group Insights: ASEAN, GCC, European Union, BRICS, G7, and NATO

ASEAN markets are increasingly important for cost-effective casting & splinting as Indonesia, Vietnam, Thailand, Malaysia, and the Philippines expand hospital capacity, emergency care access, and outpatient orthopedic services. The GCC is moving toward premium healthcare infrastructure, with Saudi Arabia, the United Arab Emirates, Qatar, Kuwait, Bahrain, and Oman emphasizing advanced hospital systems, medical tourism, emergency preparedness, and procurement standards that favor reliable orthopedic immobilization products with consistent quality and documentation.

The European Union is a quality- and compliance-driven market where CE-marked medical devices, medical device regulation, sustainability policy, and value-based purchasing influence supplier selection. BRICS economies combine scale and localization opportunities, particularly in China, India, and Brazil, while Russia and South Africa support demand through trauma care and public hospital needs. G7 markets represent advanced clinical adoption, high regulatory expectations, and strong demand for evidence-backed materials. NATO countries add defense medical readiness and trauma-care preparedness as relevant demand factors for splints, field immobilization, emergency orthopedic supplies, and deployable fracture stabilization solutions.

Key Country Insights Across Major Casting & Splinting Markets

The United States is the largest innovation and demand center in North America, supported by emergency departments, ambulatory orthopedic networks, sports medicine, pediatric orthopedics, and workers' compensation care. Canada emphasizes publicly funded access, standardized procurement, and evidence-based clinical practice, while Mexico benefits from private healthcare growth, urban hospital expansion, medical tourism, and proximity to North American medical supply chains. Brazil is Latin America's anchor market, driven by trauma care, sports injuries, road accidents, and expanding private hospital systems.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine aging populations with mature orthopedic pathways, fracture liaison services, and established hospital networks, while Russia maintains demand through trauma and hospital-based care. China and India offer substantial volume potential due to population scale, healthcare infrastructure expansion, and rising access to emergency and orthopedic services. Japan and South Korea favor high-quality, precision-oriented products supported by advanced clinical standards and aging demographics, and Australia supports demand through sports medicine, emergency care access, rural trauma needs, and established regulatory and clinical standards.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize product portfolios that balance clinical performance, affordability, and ease of use. A strong strategy includes fiberglass and plaster options, thermoplastic splints, prefabricated braces, waterproof liners, breathable padding, pediatric-friendly products, radiolucent materials, and procedure kits for emergency and outpatient settings. Suppliers should generate clinical evidence on comfort, skin integrity, application time, durability, moisture control, fracture stabilization, and patient adherence.

Commercial execution should focus on clinician education, distributor reliability, regional regulatory readiness, and digital enablement. Companies that invest in AI-assisted sizing, 3D scanning partnerships, sustainable materials, localized manufacturing, resilient inventory planning, and multilingual patient education will be better positioned to serve both premium hospital systems and cost-sensitive trauma networks without compromising safety or quality.

Research Methodology

This executive summary is developed using a structured secondary-research methodology aligned with established market intelligence standards. Inputs include public health data from organizations such as the World Health Organization, International Osteoporosis Foundation, national health agencies, regulatory bodies, hospital-care indicators, medical device guidance, and peer-reviewed orthopedic literature relevant to fracture immobilization, musculoskeletal injury management, trauma care, osteoporosis-related fractures, and rehabilitation pathways.

Market interpretation applies triangulation across epidemiology, healthcare infrastructure, product adoption, regional reimbursement dynamics, regulatory pathways, material innovation, clinical workflow trends, and supply-chain factors. Insights are intentionally presented without unsupported market-size claims; emphasis is placed on verifiable demand drivers, clinically recognized use cases, and observable technology shifts affecting casting supplies, splinting materials, and orthopedic immobilization solutions.

Conclusion

The casting & splinting industry is evolving from basic immobilization toward a more integrated orthopedic care category shaped by advanced materials, outpatient treatment, digital customization, and AI-supported decision-making. Core demand remains resilient because fractures, sprains, trauma, sports injuries, occupational injuries, post-operative repairs, and age-related bone fragility continue to require timely stabilization and follow-up care.

Competitive advantage will depend on clinical trust, product reliability, regional adaptability, regulatory compliance, supply continuity, and measurable improvements in patient experience. Manufacturers, distributors, and healthcare providers that align innovation with affordability, sustainability, safety, and workflow efficiency will be best placed to strengthen their position across mature and emerging orthopedic immobilization markets.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Casting & Splinting Market, by Product Type

• 7.1. Fiberglass Casts
• 7.2. Plaster Casts
• 7.3. Splints
  • 7.3.1. Dynamic Splints
  • 7.3.2. Static Splints
• 7.4. Synthetic Casts
• 7.5. Thermoplastic Casts

8. Casting & Splinting Market, by Material

• 8.1. Fiberglass
• 8.2. Plaster Of Paris
• 8.3. Thermoplastics
  • 8.3.1. High Temperature Thermoplastics
  • 8.3.2. Low Temperature Thermoplastics

9. Casting & Splinting Market, by Application

• 9.1. Corrective Casting
• 9.2. Fractures
  • 9.2.1. Lower Limb Fractures
  • 9.2.2. Upper Limb Fractures
• 9.3. Post Operative Immobilization

10. Casting & Splinting Market, by End User

• 10.1. Ambulatory Surgical Centers
• 10.2. Home Healthcare
• 10.3. Hospitals
  • 10.3.1. Private Hospitals
  • 10.3.2. Public Hospitals
• 10.4. Orthopedic Clinics

11. Casting & Splinting Market, by Distribution Channel

• 11.1. Online
• 11.2. Offline

12. Casting & Splinting Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Casting & Splinting Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Casting & Splinting Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. 3M Company
• 16.2. AliMed, Inc.
• 16.3. Bauerfeind AG
• 16.4. Bird & Cronin, Inc.
• 16.5. Breg, Inc.
• 16.6. Cardinal Health, Inc.
• 16.7. Corflex, Inc.
• 16.8. DeRoyal Industries, Inc.
• 16.9. Enovis Corporation
• 16.10. Essity Aktiebolag
• 16.11. Johnson & Johnson
• 16.12. Lohmann & Rauscher GmbH & Co. KG
• 16.13. McKesson Corporation
• 16.14. Medi GmbH & Co. KG
• 16.15. Medline Industries, LP
• 16.16. Orfit Industries NV
• 16.17. Prime Medical, Inc.
• 16.18. Smith & Nephew plc
• 16.19. Spencer Italia S.r.l.
• 16.20. Zimmer Biomet Holdings, Inc.
• 16.21. Ossur hf.